TOLCAPONE

Post-LOE

Alvogen

ANDAORALTABLET

Approved

Jul 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

Drug data last refreshed 23h ago

$0.0BPart D

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (2)

NCT03591757Phase 1Completed

Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)

Started Oct 2018

10 enrolled

Transthyretin AmyloidosisAmyloidosis, Leptomeningeal, Transthyretin-Related

NCT03633591Phase 1Completed

A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone

Started Jun 2018

12 enrolled

Healthy Volunteers

Company

Worked on TOLCAPONE at Alvogen? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.